Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Ken Bahk, Tim Patno, Chad Mirkin, Warren Kocmond

Premium

Nanosphere said this week that it has appointed Ken Bahk as chief strategy officer, a new position, and that CTO Tim Patno and board member Chad Mirkin will be leaving the company.

Bahk was part of Nanosphere's initial team, and served with the company until 2008. In the new post, he will be responsible for driving strategic plans and revenues in molecular diagnostics.

He currently is a director of investments at Lurie Investments, where he focuses on the diagnostics and life sciences areas. He also formerly was chair of strategic opportunities for the Association for Molecular Pathology.


Cepheid disclosed during its first-quarter earnings call last week that Warren Kocmond will join the company on May 6 as executive vice president of global operations.

Kocmond is currently vice president of global operations for Lam Research, and has previously served as executive vice president of memory products at Verigy; CEO of Electroglas; and senior vice president of global operations at Affymetrix.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.